Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
MEKINIST (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
MEKINIST
Date registered
Evaluation commenced
Decision date
Approval time
202 working days (255)
Active ingredients
trametinib
Registration type
EOI
Indication
Anaplastic thyroid cancer (ATC)
MEKINIST (film-coated tablet) in combination with dabrafenib is now also indicated for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with a BRAF V600 mutation and with no satisfactory locoregional treatment options.
Non-small cell lung cancer (NSCLC)
MEKINIST in combination with dabrafenib is now also indicated for the treatment of patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.